Is Pola-R-CHP a suitable standard for all or should the lack of survival benefit and differential subgroup responses give pause in treating all patients who qualify?

Under the new leadership of Marty Makary, the FDA should focus more attention on the critical role of real-world clinical data — such as from health insurance databases — in the ongoing assessment of ...

The efficacy and safety of currently approved and pipeline medications for moderate-to-severe hidradenitis suppurativa (HS) ...

University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides ...

This is not the first trial to show a lack of benefit when adding immunotherapy to SBRT in patients with early-stage, inoperable NSCLC.

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

NIH budget cuts are threatening key medical research programs, shrinking training grants, and leaving young researchers ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable ...

By adopting FDA-endorsed endpoints that are easier to achieve, Dimerix has bolstered the chances of its pivotal kidney drug trial succeeding.

We read with great interest the published results of the RADIOSA trial by Giulia Marvaso and colleagues.1 This well designed ...